Senti Biosciences Inc (SNTI) Stock Price, Quote & News

Company Profile

Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company's product candidates also include SENTI-202, a logic gated off-the-shelf...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 239 2030

Website: www.sentibio.com

Address:

2 Corporate Drive, First Floor, South San Francisco, United States

d_risk Nov. 13 at 10:30 PM

$SNTI - Senti Biosciences, Inc. - 10Q - Updated Risk Factors SNTI’s latest 10-Q risk factors spotlight resolved internal control weaknesses but warn of future lapses, highlight early clinical setbacks (notably SN301A toxicity), stress ongoing funding and going concern doubts, expand on manufacturing and supply chain vulnerabilities, detail IP and regulatory hurdles, and warn of dilution, stock volatility, and operational risks from leadership turnover, partnerships, and market competition. #Biotechnology #RegulatoryCompliance #ManufacturingChallenges #FinancialRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/SNTI/10-Q/2025-11-13

0 · Reply

AllandaleCapital Nov. 13 at 9:52 PM

$SNTI on watch for raise off data. They need $ and the catalyst is on its way.

0 · Reply

aletz Nov. 13 at 3:27 PM

$SNTI https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk3/ It moved up to 4th from last week's list. Let's see

0 · Reply

Love_To_Learn Nov. 12 at 10:44 PM

hmmmm SNTI does have something coming up quite soon rather sooner than i d like minor delay just a tad will suffice $SNTI

0 · Reply

aletz Nov. 6 at 9:32 PM

$SNTI https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk2/ #6 on the list

0 · Reply

winners18 Nov. 5 at 9:50 PM

$SNTI $15

1 · Reply

7m3835d3 Nov. 4 at 8:11 PM

$SNTI wtf?

1 · Reply

None_ Nov. 4 at 2:10 AM

$SNTI https://www.globenewswire.com/news-release/2025/11/03/3179400/0/en/Senti-Bio-to-Present-Updated-Clinical-Results-of-First-in-Class-Logic-Gated-CD33-FLT3-Cell-Therapy-SENTI-202-at-the-American-Society-of-Hematology-ASH-Annual-Meeting-2025.html

2 · Reply

DARKP00L Nov. 3 at 2:44 PM

$SNTI 09:13 on Nov. 03 2025 Senti Biosciences Says SENTI-202 Shows Deep, Durable Remissions In R/R AML With Selective Cancer Killing Ahead Of ASH 2025 Presentations #tradeideas

0 · Reply

Moneypa Nov. 3 at 2:16 PM

$SNTI Senti Biosciences Says SENTI-202 Shows Deep, Durable Remissions In R/R AML With Selective Cancer Killing Ahead Of ASH 2025 Presentations

0 · Reply

Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December

Nov 3, 2025, 9:05 AM EST - 11 days ago

Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025

Oct 16, 2025, 9:05 AM EDT - 4 weeks ago

Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference

Oct 6, 2025, 9:05 AM EDT - 5 weeks ago

Senti Bio to Present at BioJapan

Sep 18, 2025, 9:15 AM EDT - 2 months ago

Senti Bio to Present at the MedInvest Biotech & Pharma Conference

Sep 2, 2025, 9:05 AM EDT - 2 months ago

Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 9:15 AM EDT - 3 months ago

Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 12, 2025, 9:15 AM EDT - 3 months ago

Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

Aug 7, 2025, 8:05 AM EDT - 3 months ago

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

$Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia$

Aug 5, 2025, 8:30 AM EDT - 3 months ago

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

Jul 22, 2025, 8:45 AM EDT - 4 months ago

Senti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 21, 2025, 8:55 AM EDT - 4 months ago

Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

Jul 18, 2025, 8:55 AM EDT - 4 months ago

Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors

Jun 30, 2025, 9:15 AM EDT - 4 months ago

Senti Bio Participates in Nasdaq Amplify Spotlight Series

Jun 24, 2025, 8:45 AM EDT - 5 months ago

Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference

Jun 18, 2025, 7:00 AM EDT - 5 months ago

Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia

Jun 9, 2025, 4:30 PM EDT - 5 months ago

Senti Biosciences Announces New Employment Inducement Grants

Jun 6, 2025, 9:05 AM EDT - 5 months ago

Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC

May 30, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Shareholders to Inquire about Securities Investigation

May 29, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Connect

May 28, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Reach Out

May 27, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Shareholders to Learn More About the Investigation

May 26, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Investors to Learn More About the Investigation

May 25, 2025, 10:00 AM EDT - 6 months ago

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 23, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Investors to Connect

May 22, 2025, 4:05 PM EDT - 6 months ago

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 22, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Stockholders to Inquire about Securities Investigation

May 22, 2025, 8:30 AM EDT - 6 months ago

Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202

May 21, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Investors to Inquire about Securities Investigation

May 20, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Investors to Reach Out

May 20, 2025, 5:28 AM EDT - 6 months ago

SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm

May 19, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Stockholders to Reach Out

May 18, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Stockholders to Connect

May 16, 2025, 2:00 PM EDT - 6 months ago

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 8, 2025, 8:35 AM EDT - 6 months ago

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202

May 6, 2025, 4:35 PM EDT - 6 months ago

Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development

May 1, 2025, 9:15 AM EDT - 7 months ago

Senti Bio Releases Virtual Investor “What This Means” Segment

Apr 30, 2025, 9:00 AM EDT - 7 months ago

Senti Bio to Present at the Citizens JMP Life Sciences Conference

$Senti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML$

Apr 28, 2025, 7:00 AM EDT - 7 months ago

Senti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML

d_risk Nov. 13 at 10:30 PM

0 · Reply

AllandaleCapital Nov. 13 at 9:52 PM

$SNTI on watch for raise off data. They need $ and the catalyst is on its way.

0 · Reply

aletz Nov. 13 at 3:27 PM

$SNTI https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk3/ It moved up to 4th from last week's list. Let's see

0 · Reply

Love_To_Learn Nov. 12 at 10:44 PM

hmmmm SNTI does have something coming up quite soon rather sooner than i d like minor delay just a tad will suffice $SNTI

0 · Reply

aletz Nov. 6 at 9:32 PM

$SNTI https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk2/ #6 on the list

0 · Reply

winners18 Nov. 5 at 9:50 PM

$SNTI $15

1 · Reply

7m3835d3 Nov. 4 at 8:11 PM

$SNTI wtf?

1 · Reply

None_ Nov. 4 at 2:10 AM

2 · Reply

DARKP00L Nov. 3 at 2:44 PM

$SNTI 09:13 on Nov. 03 2025 Senti Biosciences Says SENTI-202 Shows Deep, Durable Remissions In R/R AML With Selective Cancer Killing Ahead Of ASH 2025 Presentations #tradeideas

0 · Reply

Moneypa Nov. 3 at 2:16 PM

$SNTI Senti Biosciences Says SENTI-202 Shows Deep, Durable Remissions In R/R AML With Selective Cancer Killing Ahead Of ASH 2025 Presentations

0 · Reply

winners18 Nov. 3 at 4:11 AM

$SNTI count down starting tomorrow!

1 · Reply

winners18 Nov. 1 at 10:25 PM

$SNTI last time data news caused share price to jump to $10!

0 · Reply

Love_To_Learn Oct. 27 at 12:57 PM

$SNTI $DTSS making a few changes to u 2

0 · Reply

winners18 Oct. 25 at 5:16 PM

$SNTI mentioned potential BTD from last presentation

0 · Reply

Kingcrab3333 Oct. 24 at 5:13 PM

$SNTI

0 · Reply

Lexxy86 Oct. 24 at 2:38 PM

$SNTI Dropping data soon. Easy $12

0 · Reply

winners18 Oct. 24 at 3:58 AM

$SNTI 20 pts data will be presented at ash. If data continue to impress, sky is the limit.

0 · Reply

winners18 Oct. 24 at 3:56 AM

$SNTI https://www.fiercebiotech.com/biotech/ipsen-writes-check-worth-eu1b-acquire-next-gen-cancer-biotech

0 · Reply

winners18 Oct. 24 at 3:52 AM

$SNTI https://www.targetedonc.com/view/ict01-boosts-aml-remission-and-survival-in-eviction-trial

1 · Reply

Lexxy86 Oct. 23 at 12:54 AM

$SNTI only a matter of time here

0 · Reply

Moneymike314 Oct. 22 at 2:41 PM

$SNTI excited yet patiently waiting for this to be 2.75+ and reading all the comments from fomo and the like

0 · Reply

AnaDiggs836 Oct. 21 at 4:50 PM

$SNTI developing biotech recovery; AITX recovering markets through AI precision — confirmed profitability and efficiency gains.

0 · Reply

Market Cap	49.44M
Revenue (ttm)	0.00
Net Income (ttm)	-52.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	128,800
Avg Vol	193,048
Day's Range	N/A - N/A
Shares Out	26.16M
Stochastic %K	12%
Beta	2.09
Analysts	Strong Sell
Price Target	$12.00